Modulation of miRNAs in pulmonary hypertension

International Journal of Hypertension

Volumn 2015, Issue , 2015, Pages

  Gupta, Sudhiranjan ^a,b,c   Li, Li ^a,d  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; ENOXIMONE; EXPORTIN 5; ILOPROST; KRUPPEL LIKE FACTOR 4; KRUPPEL LIKE FACTOR 5; MICRORNA; MICRORNA 130; MICRORNA 14; MICRORNA 143; MICRORNA 145; MICRORNA 146; MICRORNA 17 92; MICRORNA 204; MICRORNA 26A; MICRORNA 301; MILRINONE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTACYCLIN; PROSTAGLANDIN E1; PROTEIN BCL 2; PROTEIN TYROSINE PHOSPHATASE SHP 2; SILDENAFIL; STAT3 PROTEIN; TADALAFIL; TRANSCRIPTION FACTOR NFAT; TREPROSTINIL; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTERY ENDOTHELIUM; BIOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE SEVERITY; DOWN REGULATION; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HYPOXIA; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; PATHOGENESIS; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION; UPREGULATION; VASCULAR REMODELING;

EID: 84925727345     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2015/169069     Document Type: Review

References (113)

1. M. Humbert, D. Montani, O. V. Evgenov, and G. Simonneau, "Defnition and classifcation of pulmonary hypertension," Handbook of Experimental Pharmacology, vol. 218, pp. 3-29, 2013.
2. C. Guignabert and P. Dorfmuller, "Pathology and pathobiology of pulmonary hypertension," Seminars in Respiratory and Critical Care Medicine, vol. 34, no. 5, pp. 551-559, 2013.
3. R. M. Tuder, E. Stacher, J. Robinson, R. Kumar, and B. B. Graham, "Pathology of pulmonary hypertension," Clinics in Chest Medicine, vol. 34, no. 4, pp. 639-650, 2013.
4. B. A. Maron and J. Loscalzo, "Pulmonary hypertension: patho-physiology and signaling pathways," Handbook of Experimental Pharmacology, vol. 218, pp. 31-58, 2013.
5. "New developments in pulmonary hypertension/pulmonary arterial hypertension. Proceedings of Pulmonary Hypertension UP2DATE 2008-post Dana Point. March 14-15, 2008. Munich, Germany," Deutsche Medizinische Wochenschrif, vol. 133, supplement 6, pp. S165-S218, 2008.
6. G. Simonneau, I. M. Robbins, M. Beghetti et al., "Updated clinical classifcation of pulmonary hypertension," Journal of the American College of Cardiology, vol. 54, no. 1, supplement, pp. S43-S54, 2009.
7. M. Humbert, N. W. Morrell, S. L. Archer et al., "Cellular and molecular pathobiology of pulmonary arterial hypertension," Journal of the American College of Cardiology, vol. 43, no. 12, supplement S, pp. 13S-24S, 2004.
8. A. Shifren, A. G. Durmowicz, R. H. Knutsen, G. Faury, and R. P. Mecham, "Elastin insufciency predisposes to elevated pulmonary circulatory pressures through changes in elastic artery structure," Journal of Applied Physiology, vol. 105, no. 5, pp. 1610-1619, 2008.
9. L. A. Shimoda and S. S. Laurie, "Vascular remodeling in pulmonary hypertension," Journal of Molecular Medicine, vol. 91, no. 3, pp. 297-309, 2013.
10. A. Vonk-Noordegraaf, F. Haddad, K. M. Chin et al., "Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology," Journal of the American College of Cardiology, vol. 62, no. 25, supplement, pp. D22-D33, 2013.
11. V. Franco, "Right ventricular remodeling in pulmonary hypertension," Heart Failure Clinics, vol. 8, no. 3, pp. 403-412, 2012.
12. T. G. di Salvo, "Pulmonary hypertension and right ventricular failure in lef ventricular systolic dysfunction," Current Opinion in Cardiology, vol. 27, no. 3, pp. 262-272, 2012.
13. L. R. Frumkin, "Te pharmacological treatment of pulmonary arterial hypertension," Pharmacological Reviews, vol. 64, no. 3, pp. 583-620, 2012.
14. R. Nogueira-Ferreira and T. Henriques-Coelho, "Cellular interplay in pulmonary arterial hypertension: implications for new therapies," Biochimica et Biophysica Acta-Molecular Cell Research, vol. 1843, no. 5, pp. 885-893, 2014.
15. S. S. Pullamsetti, R. Schermuly, A. Ghofrani, N. Weissmann, F. Grimminger, and W. Seeger, "Novel and emerging therapies for pulmonary hypertension," The American Journal of Respiratory and Critical Care Medicine, vol. 189, no. 4, pp. 394-400, 2014.
16. A. Seferian and G. Simonneau, "Terapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?" European Respiratory Review, vol. 22, no. 129, pp. 217-226, 2013.
17. N. Brunner, V. A. de Jesus Perez, A. Richter et al., "Perioperative pharmacological management of pulmonary hypertensive crisis during congenital heart surgery," Pulmonary Circulation, vol. 4, no. 1, pp. 10-24, 2014.
18. L. Lindberg, A. K. Olsson, P. Jögi, and C. Jonmarker, "How common is severe pulmonary hypertension afer pediatric cardiac surgery?" Journal of Toracic and Cardiovascular Surgery, vol. 123, no. 6, pp. 1155-1163, 2002.
19. Y. Wang, X.-Y. Xue, Y.-X. Liu et al., "Pulmonary arterial hypertension and MicroRNAs-an ever-growing partnership," Archives of Medical Research, vol. 44, no. 7, pp. 483-487, 2013.
20. P. Caruso, M. R. MacLean, R. Khanin et al., "Dynamic changes in lung microRNA profles during the development of pulmonary hypertension due to chronic hypoxia and monocro-taline," Arteriosclerosis, Trombosis, and Vascular Biology, vol. 30, no. 4, pp. 716-723, 2010.
21. K. M. Drake, D. Zygmunt, L. Mavrakis et al., "Altered MicroRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8," The American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 12, pp. 1400-1408, 2011.
22. S. S. Pullamsetti, C. Doebele, A. Fischer et al., "Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension," American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 4, pp. 409-419, 2012.
23. S. Yang, S. Banerjee, A. de Freitas et al., "miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 302, no. 6, pp. L521-L529, 2012.
24. P. Caruso, Y. Dempsie, H. C. Stevens et al., "A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples," Circulation Research, vol. 111, no. 3, pp. 290-300, 2012.
25. A. Lee, D. McLean, J. Choi, H. Kang, W. Chang, and J. Kim, "Terapeutic implications of microRNAs in pulmonary arterial hypertension," BMB Reports, vol. 47, no. 6, pp. 311-317, 2014.
26. D. Z. Wang and X. L. Zheng, "Induction of microRNA-1 by myocardin in smooth muscle cells inhibits cell proliferation," Arteriosclerosis, Trombosis, and Vascular Biology, vol. 31, no. 2, pp. 368-375, 2011.
27. C. Xie, H. Huang, X. Sun et al., "MicroRNA-1 regulates smooth muscle cell diferentiation by repressing kruppel-like factor 4," Stem Cells and Development, vol. 20, no. 2, pp. 205-210, 2011.
28. G. Liu, A. Friggeri, Y. Yang et al., "miR-21 mediates fbrogenic activation of pulmonary fbroblasts and lung fbrosis," The Journal of Experimental Medicine, vol. 207, no. 8, pp. 1589-1597, 2010.
29. M. C. Chan, A. C. Hilyard, C. Wu et al., "Molecular basis for antagonism between PDGF and the TGF family of signalling pathways by control of miR-24 expression," The EMBO Journal, vol. 29, no. 3, pp. 559-573, 2010.
30. N. J. Leeper, A. Raiesdana, Y. Kojima et al., "MicroRNA-26a is a novel regulator of vascular smooth muscle cell function," Journal of Cellular Physiology, vol. 226, no. 4, pp. 1035-1043, 2011.
31. Y. Cheng, X. Liu, J. Yang et al., "MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation," Circulation Research, vol. 105, no. 2, pp. 158-166, 2009.
32. K. R. Cordes, N. T. Sheehy, M. P. White et al., "MiR-145 and miR-143 regulate smooth muscle cell fate and plasticity," Nature, vol. 460, no. 7256, pp. 705-710, 2009.
33. T. Boettger, N. Beetz, S. Kostin et al., "Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster," The Journal of Clinical Investigation, vol. 119, no. 9, pp. 2634-2647, 2009.
34. S. G. Sun, B. Zheng, M. Han et al., "MiR-146a and Krüppel-like factor 4 form a feedback loop to participate in vascular smooth muscle cell proliferation," EMBO Reports, vol. 12, no. 1, pp. 56-62, 2011.
35. X. Liu, Y. Cheng, S. Zhang, Y. Lin, J. Yang, and C. Zhang, "A Necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia," Circulation Research, vol. 104, no. 4, pp. 476-486, 2009.
36. C. Le Sage, R. Nagel, D. A. Egan et al., "Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation," EMBO Journal, vol. 26, no. 15, pp. 3699-3708, 2007.
37. D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and functio," Cell, vol. 116, no. 2, pp. 281-297, 2004.
38. R. W. Carthew and E. J. Sontheimer, "Origins and Mechanisms of miRNAs and siRNAs," Cell, vol. 136, no. 4, pp. 642-655, 2009.
39. M. K. Meshesha, I. Veksler-Lublinsky, O. Isakov et al., "Te microRNA transcriptome of human cytomegalovirus (HCMV)," The Open Virology Journal, vol. 6, pp. 38-48, 2012.
40. A. Kozomara and S. Grifths-Jones, "MiRBase: integrating microRNA annotation and deep-sequencing data," Nucleic Acids Research, vol. 39, no. 1, pp. D152-D157, 2011.
41. V. N. Kim, "MicroRNA biogenesis: coordinated cropping and dicing," Nature Reviews Molecular Cell Biology, vol. 6, no. 5, pp. 376-385, 2005.
42. X. Cai, C. H. Hagedorn, and B. R. Cullen, "Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs," RNA, vol. 10, no. 12, pp. 1957-1966, 2004.
43. R. I. Gregory, K.-P. Yan, G. Amuthan et al., "Te Microprocessor complex mediates the genesis of microRNAs," Nature, vol. 432, no. 7014, pp. 235-240, 2004.
44. A. Stroynowska-Czerwinska, A. Fiszer, and W. J. Krzyzosiak, "Te panorama of miRNA-mediated mechanisms in mammalian cells," Cellular and Molecular Life Sciences, vol. 71, no. 12, pp. 2253-2270, 2014.
45. J. Han, Y. Lee, K.-H. Yeom, Y.-K. Kim, H. Jin, and V. N. Kim, "Te Drosha-DGCR8 complex in primary microRNA processing," Genes and Development, vol. 18, no. 24, pp. 3016-3027, 2004.
46. M. Morlando, M. Ballarino, N. Gromak, F. Pagano, I. Bozzoni, and N. J. Proudfoot, "Primary microRNA transcripts are processed co-transcriptionally," Nature Structural and Molecular Biology, vol. 15, no. 9, pp. 902-909, 2008.
47. J. Bauersachs and T. Tum, "Biogenesis and regulation of cardiovascular MicroRNAs," Circulation Research, vol. 109, no. 3, pp. 334-347, 2011.
48. Y. K. Kim and V. N. Kim, "Processing of intronic microRNAs," The EMBO Journal, vol. 26, no. 3, pp. 775-783, 2007.
49. Y. Lee, C. Ahn, J. Han et al., "Te nuclear RNase III Drosha initiates microRNA processing," Nature, vol. 425, no. 6956, pp. 415-419, 2003.
50. E. Berezikov, W.-J. Chung, J. Willis, E. Cuppen, and E. C. Lai, "Mammalian mirtron genes," Molecular Cell, vol. 28, no. 2, pp. 328-336, 2007.
51. S. Chelouf, C. O. Dos Santos, M. M. W. Chong, and G. J. Hannon, "A dicer-independent miRNA biogenesis pathway that requires Ago catalysis," Nature, vol. 465, no. 7298, pp. 584-589, 2010.
52. R. Yi, Y. Qin, I. G. Macara, and B. R. Cullen, "Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs," Genes and Development, vol. 17, no. 24, pp. 3011-3016, 2003.
53. T. P. Chendrimada, R. I. Gregory, E. Kumaraswamy et al., "TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing," Nature, vol. 436, no. 7051, pp. 740-744, 2005.
54. K. H. Kok, M.-H. J. Ng, Y.-P. Ching, and D.-Y. Jin, "Human TRBP and PACT directly interact with each other and associate with dicer to facilitate the production of small interfering RNA," The Journal of Biological Chemistry, vol. 282, no. 24, pp. 17649-17657, 2007.
55. E. Koscianska, J. Starega-Roslan, and W. J. Krzyzosiak, "Te role of dicer protein partners in the processing of microRNA precursors," PLoS ONE, vol. 6, no. 12, Article ID e28548, 2011.
56. E. Bernstein, A. A. Caudy, S. M. Hammond, and G. J. Hannon, "Role for a bidentate ribonuclease in the initiation step of RNA interference," Nature, vol. 409, no. 6818, pp. 363-366, 2001.
57. G. Meister, "Argonaute proteins: Functional insights and emerging roles," Nature Reviews Genetics, vol. 14, no. 7, pp. 447-459, 2013.
58. A. Lingel, B. Simon, E. Izaurralde, and M. Sattler, "Nucleic acid 3′-end recognition by the Argonaute2 PAZ domain," Nature Structural and Molecular Biology, vol. 11, no. 6, pp. 576-577, 2004.
59. D. S. Schwarz, G. Hutvágner, T. Du, Z. Xu, N. Aronin, and P. D. Zamore, "Asymmetry in the assembly of the RNAi enzyme complex," Cell, vol. 115, no. 2, pp. 199-208, 2003.
60. D. Baek, J. Vilĺen, C. Shin, F. D. Camargo, S. P. Gygi, and D. P. Bartel, "Te impact of microRNAs on protein output," Nature, vol. 455, no. 7209, pp. 64-71, 2008.
61. M. Selbach, B. Schwanhäusser, N. Tierfelder, Z. Fang, R. Khanin, and N. Rajewsky, "Widespread changes in protein synthesis induced by microRNAs," Nature, vol. 455, no. 7209, pp. 58-63, 2008.
62. J. Kim, Y. Kang, Y. Kojima et al., "An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension," Nature Medicine, vol. 19, no. 1, pp. 74-82, 2013.
63. B. N. Davis, A. C. Hilyard, G. Lagna, and A. Hata, "SMAD proteins control DROSHA-mediated microRNA maturation," Nature, vol. 454, no. 7200, pp. 56-61, 2008.
64. R. Ji, Y. Cheng, J. Yue et al., "MicroRNA expression signature and antisense-mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation," Circulation Research, vol. 100, no. 11, pp. 1579-1588, 2007.
65. A. Courboulin, R. Paulin, N. J. Gigùere et al., "Role for miR-204 in human pulmonary arterial hypertension," The Journal of Experimental Medicine, vol. 208, no. 3, pp. 535-548, 2011.
66. C. Wei, H. Henderson, C. Spradley et al., "Circulating miRNAs as potential marker for pulmonary hypertension," PLoS ONE, vol. 8, no. 5, Article ID e64396, 2013.
67. C. L. Bockmeyer, L. Maegel, S. Janciauskiene et al., "Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression," Journal of Heart and Lung Transplantation, vol. 31, no. 7, pp. 764-772, 2012.
68. B. N. Davis-Dusenbery, M. C. Chan, K. E. Reno et al., "Down-regulation of Krüppel-like Factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-and bone morphogenetic protein 4," Journal of Biological Chemistry, vol. 286, no. 32, pp. 28097-28110, 2011.
69. X. Long and J. M. Miano, "Transforming growth factor-α1 (TGF-α1) utilizes distinct pathways for the transcriptional activation of microRNA 143/145 in human coronary artery smooth muscle cells," Journal of Biological Chemistry, vol. 286, no. 34, pp. 30119-30129, 2011.
70. V. Pospisil, K. Vargova, J. Kokavec et al., "Epigenetic silencing of the oncogenic miR-17-92 cluster during PU.1-directed macrophage diferentiation," The EMBO Journal, vol. 30, no. 21, pp. 4450-4464, 2011.
71. M. Brock, M. Trenkmann, R. E. Gay et al., "Interleukin-6 modulates the expression of the bone morphogenic protein receptor type ii through a novel STAT3-microRNA cluster 17/92 pathway," Circulation Research, vol. 104, no. 10, pp. 1184-1191, 2009.
72. M. Brock, V. J. Samillan, M. Trenkmann et al., "AntagomiR directed against miR-20a restores functional BMPR2 signalling and prevents vascular remodelling in hypoxia-induced pulmonary hypertension," European Heart Journal, vol. 35, no. 45, pp. 3203-3211, 2014.
73. T. Bertero, Y. Lu, and S. Annis, "Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension," Journal of Clinical Investigation, vol. 124, no. 8, pp. 3514-3528, 2014.
74. G. G. Pietra, F. Capron, S. Stewart et al., "Pathologic assessment of vasculopathies in pulmonary hypertension," Journal of the American College of Cardiology, vol. 43, no. 12, supplement S, pp. 25S-32S, 2004.
75. K. Abe, M. Toba, A. Alzoubi et al., "Formation of plexiform lesions in experimental severe pulmonary arterial hypertension," Circulation, vol. 121, no. 25, pp. 2747-2754, 2010.
76. K. R. Stenmark, N. Davie, M. Frid, E. Gerasimovskaya, and M. Das, "Role of the adventitia in pulmonary vascular remodeling," Physiology, vol. 21, no. 2, pp. 134-145, 2006.
77. M. Das, E. C. Dempsey, J. T. Reeves, and K. R. Stenmark, "Selective expansion of fbroblast subpopulations from pulmonary artery adventitia in response to hypoxia," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 282, no. 5, pp. L976-L986, 2002.
78. K. R. Stenmark, D. Bouchey, R. Nemenof, E. C. Dempsey, and M. Das, "Hypoxia-induced pulmonary vascular remodeling: contribution of the adventitial fbroblasts," Physiological Research, vol. 49, no. 5, pp. 503-517, 2000.
79. G. Lagna, M. M. Ku, P. H. Nguyen, N. A. Neuman, B. N. Davis, and A. Hata, "Control of phenotypic plasticity of smooth muscle cells by bone morphogenetic protein signaling through the myocardin-related transcription factors," The Journal of Biological Chemistry, vol. 282, no. 51, pp. 37244-37255, 2007.
80. A. Y. Rangrez, Z. A. Massy, V. M.-L. Meuth, and L. Metzinger, "MiR-143 and miR-145 molecular keys to switch the phenotype of vascular smooth muscle cells," Circulation: Cardiovascular Genetics, vol. 4, no. 2, pp. 197-205, 2011.
81. M. Xin, E. M. Small, L. B. Sutherland et al., "MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury," Genes and Development, vol. 23, no. 18, pp. 2166-2178, 2009.
82. K. R. Cordes, N. T. Sheehy, M. P. White et al., "miR-145 and miR-143 regulate smooth muscle cell fate and plasticity," Nature, vol. 460, no. 7256, pp. 705-710, 2009.
83. L. Elia, M. Quintavalle, J. Zhang et al., "Te knockout of miR-143 and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease," Cell Death and Diferentiation, vol. 16, no. 12, pp. 1590-1598, 2009.
84. B. N. Davis, A. C. Hilyard, P. H. Nguyen, G. Lagna, and A. Hata, "Induction of MicroRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype," Journal of Biological Chemistry, vol. 284, no. 6, pp. 3728-3738, 2009.
85. S. Albinsson and W. C. Sessa, "Can microRNAs control vascular smooth muscle phenotypic modulation and the response to injury?" Physiological Genomics, vol. 43, no. 10, pp. 529-533, 2011.
86. D. Gou, R. Ramchandran, X. Peng et al., "Mir-210 has an antiapoptotic efect in pulmonary artery smooth muscle cells during hypoxia," The American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 303, no. 8, pp. L682-L691, 2012.
87. K. Kang, X. Peng, X. Zhang et al., "MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells," Journal of Biological Chemistry, vol. 288, no. 35, pp. 25414-25427, 2013.
88. S. Li, Y. Ran, D. Zhang, J. Chen, and D. Zhu, "MicroRNA-138 plays a role in hypoxic pulmonary vascular remodeling by targeting Mst1," Biochemical Journal, vol. 452, no. 2, pp. 281-291, 2013.
89. J. Weiler, J. Hunziker, and J. Hall, "Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?" Gene Terapy, vol. 13, no. 6, pp. 496-502, 2006.
90. J. Krützfeldt, N. Rajewsky, R. Braich et al., "Silencing of microRNAs in vivo with 'antagomirs'," Nature, vol. 438, no. 7068, pp. 685-689, 2005.
91. P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., "Circulating microRNAs as stable blood-based markers for cancer detection," Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10513-10518, 2008.
92. R. Recchioni, F. Marcheselli, F. Olivieri, S. Ricci, A. D. Pro-copio, and R. Antonicelli, "Conventional and novel diagnostic biomarkers of acute myocardial infarction: a promising role for circulating microRNAs," Biomarkers, vol. 18, no. 7, pp. 547-558, 2013.
93. D.-Z. Zhang, K.-M. Lau, E. S. Y. Chan et al., "Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer," PLoS ONE, vol. 9, no. 7, Article ID e100793, 2014.
94. R. Nassirpour, S. Mathur, M. M. Gosink et al., "Identifcation of tubular injury microRNA biomarkers in urine: comparison of next-generation sequencing and qPCR-based profling platforms," BMC Genomics, vol. 15, article 485, 2014.
95. N. J. Park, H. Zhou, D. Elashof et al., "Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection," Clinical Cancer Research, vol. 15, no. 17, pp. 5473-5477, 2009.
96. J. Saikumar, D. Hofmann, T.-M. Kim et al., "Expression, circulation, and excretion profle of microRNA-21,-155, and-18a following acute kidney injury," Toxicological Sciences, vol. 129, no. 2, pp. 256-267, 2012.
97. Z. Xie, G. Chen, X. Zhang et al., "Salivary microRNAs as promising biomarkers for detection of esophageal cancer," PLoS ONE, vol. 8, no. 4, Article ID e57502, 2013.
98. K. C. Vickers, B. T. Palmisano, B. M. Shoucri, R. D. Shamburek, and A. T. Remaley, "MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins," Nature Cell Biology, vol. 13, no. 4, pp. 423-435, 2011.
99. J. D. Arroyo, J. R. Chevillet, E. M. Kroh et al., "Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 5003-5008, 2011.
100. K. Wang, S. Zhang, J. Weber, D. Baxter, and D. J. Galas, "Export of microRNAs and microRNA-protective protein by mammalian cells," Nucleic Acids Research, vol. 38, no. 20, pp. 7248-7259, 2010.
101. Y. D'Alessandra, P. Devanna, F. Limana et al., "Circulating microRNAs are new and sensitive biomarkers of myocardial infarction," European Heart Journal, vol. 31, no. 22, pp. 2765-2773, 2010.
102. X. Ji, R. Takahashi, Y. Hiura, G. Hirokawa, Y. Fukushima, and N. Iwai, "Plasma miR-208 as a biomarker of myocardial injury," Clinical Chemistry, vol. 55, no. 11, pp. 1944-1949, 2009.
103. A. J. Tijsen, E. E. Creemers, P. D. Moerland et al., "MiR423-5p as a circulating biomarker for heart failure," Circulation Research, vol. 106, no. 6, pp. 1035-1039, 2010.
104. E. E. Creemers, A. J. Tijsen, and Y. M. Pinto, "Circulating MicroRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?" Circulation Research, vol. 110, no. 3, pp. 483-495, 2012.
105. V. di Stefano, G. Zaccagnini, M. C. Capogrossi, and F. Martelli, "microRNAs as peripheral blood biomarkers of cardiovascular disease," Vascular Pharmacology, vol. 55, no. 4, pp. 111-118, 2011.
106. M. Tanaka, K. Oikawa, M. Takanashi et al., "Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients," PLoS ONE, vol. 4, no. 5, Article ID e5532, 2009.
107. G.-K. Wang, J.-Q. Zhu, J.-T. Zhang et al., "Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans," European Heart Journal, vol. 31, no. 6, pp. 659-666, 2010.
108. O. Gidlöf, P. Andersson, J. van der Pals, M. Götberg, and D. Erlinge, "Cardiospecifc microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples," Cardiology, vol. 118, no. 4, pp. 217-226, 2011.
109. Y. Akao, A. Iio, T. Itoh et al., "microvesicle-mediated RNA molecule delivery system using monocytes/macrophages," Molecular Terapy, vol. 19, no. 2, pp. 395-399, 2011.
110. X. Chen, H. Liang, J. Zhang, K. Zen, and C.-Y. Zhang, "Secreted microRNAs: a new form of intercellular communication," Tre nd s in C ell Bi olo g y, vol. 22, no. 3, pp. 125-132, 2012.
111. M. P. Hunter, N. Ismail, X. Zhang et al., "Detection of microRNA expression in human peripheral blood microvesicles," PLoS ONE, vol. 3, no. 11, Article ID e3694, 2008.
112. A. Zernecke, K. Bidzhekov, H. Noels et al., "Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection," Science Signaling, vol. 2, no. 100, p. ra81, 2009.
113. C. J. Rhodes, J. Wharton, R. A. Boon et al., "Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension," American Journal of Respiratory and Critical Care Medicine, vol. 187, no. 3, pp. 294-302, 2013.